Title of lecture: Creating A Universal Donor-Derived Cell Therapy
Dr. Thierry Wurch, Servier, France
Director of External Studies in Immuno-oncology
Servier is applying the Cellectis’ TALEN gene editing technology to overcome current limitations and provide an allogeneic, frozen, “off-the-shelf” T cell based medicinal product. UCART19 is an allogeneic CAR T-cell product candidate being developed for treatment of CD19-expressing hematological malignancies. It is currently being evaluated in a phase 1 clinical trials in relapsed/refractory acute lymphoblastic leukemia (ALL) of adult and pediatric patients. The selection of UCART19 as a candidate was based on the impressive clinical benefits leading to the marketing of the two first autologous CAR T-cell products Kymriah (Novartis) and Yescarta (Kite Gilead).
More information about the Sartorius Research Xchange Forum on Trends and Challenges in Regenerative Medicine and Cell Therapy 2018: [ Ссылка ]
